TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

Onlay mesh placement of the synthetic and fully resorbable TIGR®Matrix surgical mesh (Novus Scientific AB, Uppsala — Sweden) for the prevention of incisional hernia in septic patients undergoing emergency laparoscopy showed encouraging efficacy and safety in a small retrospective study, as presented during the XXVIII Waterford Surgical October Club Meeting.

Efficacy of Oral Cladribine in Multiple Sclerosis Durable after a 2-Year Course of Treatment

Efficacy of oral Cladribine for MS durable after a two-year treatment course

Two short courses of oral cladribine (Mavenclad®, Merck KGaA) over a period of two years can sustain the No Evidence of Disease Activity-3 (NEDA-3) status in certain relapsing-remitting multiple sclerosis (RRMS) patients for up to three additional years without further treatment, a new analysis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 suggests.

Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

On 28 November 2018, the FDA approved gilteritinib (Xospata® [ASP2215], Astellas) for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) harbouring FLT3 mutations as confirmed by an FDA-approved companion diagnostic test (CDx).

TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

On 26 November 2018, the FDA granted accelerated approval to the first-in-class tropomyosin receptor-kinase (TRK) inhibitor larotrectinib (Vitrakvi®, Loxo Oncology/Bayer) for the treatment of adult and paediatric patients with solid tumours that are metastatic or not amenable to surgery, harbour the neurotrophic receptor tyrosine kinase (NTRK) gene fusion in the absence of known acquired resistance mutations, and whose cancer progressed following treatment or for whom are no satisfactory other treatment options available.

Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

Total intravenous anaesthesia (TIVA) with propofol is associated with several advantages regarding anaesthesia maintenance including increased patient satisfaction and lower rates of postoperative pain (POP) and postoperative nausea and vomiting (PONV), as concluded by a meta-analysis published in BMC Anesthesiology.

Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

On 21 November 2018, the FDA granted accelerated approval to venetoclax (Venclexta®, AbbVie/Genentech) in combination with either azacitidine, or decitabine, or low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukaemia (AML) patients ≥75 years old or in patients with comorbidities precluding intensive induction chemotherapy.

Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients

On 21 November 2018, the FDA approved glasdegib (Daurismo®, Pfizer) in combination with low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukaemia (AML) in patients of 75 years or older and in patients with comorbidities contraindicating intensive induction chemotherapy.

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

Intraperitoneal bupivacaine to reduce postoperative opioid-use following laparoscopic appendectomy

Instilling post-operative intraperitoneal bupivacaine at the base of the caecum reduces postoperative pain scores and in-hospital opioid-use in patients undergoing laparoscopic appendectomy, as reported in the American Journal of Surgery by investigators of the Metro Health Hospital in Wyoming, MI, United States (NCT03004222).

Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

On 20 November 2018, the FDA approved the interferon-γ neutralising monoclonal antibody emapalumab (Gamifant®, Novimmune) for the treatment of adult and paediatric (newborn and older) patients with refractory, recurrent, or progressive primary haemophagocytic lymphohistiocytosis (HLH) or in patients intolerant to conventional HLH therapy.

Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas

On 16 November, 2018, the FDA approved brentuximab vedotin (Adcetris®, Seattle Genetics) in combination with chemotherapy for the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) and other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS).